Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR

G Swan; A Valdes; H Ring; T Khroyan; L Jack; C Ton; S Curry; T McAfee

doi:10.1038/sj.tpj.6500281

Back

Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR

Journal article

Peer reviewed

Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR

G Swan, A Valdes, H Ring, T Khroyan, L Jack, C Ton, S Curry and T McAfee

The pharmacogenomics journal, Vol.5(1), pp.21-29

02/01/2005

DOI: 10.1038/sj.tpj.6500281

PMID: 15492764

View Online

Abstract

The A1 allele of the dopamine D2 receptor gene (DRD2) is associated with a reduced number of dopamine binding sites in the brain and with the increased likelihood of substance abuse and addictive behavior. In a study of smokers enrolled in an open-label, randomized effectiveness trial, we investigated whether variants in the DRD2 receptor gene are associated with smoking cessation outcomes following treatment with a combination of bupropion SR and behavioral counseling. Adherence to treatment and point-prevalent smoking status were assessed at 3 and 12 months, respectively, following a target quit date. Compared to women who carry both A2 alleles, women with at least one A1 allele were more likely to report having stopped taking bupropion due to medication side effects (odds ratio (OR)=1.91, 95% confidence interval (CI)=1.01–3.60; P<0.04) and at 12 months were somewhat more likely to report smoking (OR=0.76, 95% CI=0.56–1.03; P<0.076). Significant associations or trends were not observed in men. In women, individual variability in responsiveness to bupropion-based treatment may be partially due to differences in genetic variants influencing dopamine receptor function.

Addictive behaviors

Alleles

Binding sites

Bupropion

Cigarette smoking

Dopamine

Dopamine D2 receptors

Drug abuse

Drug addiction

Genetic variance

Genotypes

Smoking cessation

Details

Title: Subtitle: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR
Creators: G Swan - SRI International
A Valdes - SRI International
H Ring - SRI International
T Khroyan - SRI International
L Jack - SRI International
C Ton - Genelex Corporation, Seattle, USA
S Curry - Group Health Cooperative
T McAfee - Group Health Cooperative
Resource Type: Journal article
Publication Details: The pharmacogenomics journal, Vol.5(1), pp.21-29
Publisher: Nature Publishing Group
DOI: 10.1038/sj.tpj.6500281
PMID: 15492764
ISSN: 1470-269X
eISSN: 1473-1150
Language: English
Date published: 02/01/2005
Academic Unit: Health Management and Policy; Community and Behavioral Health
Record Identifier: 9984366369702771

Metrics

7 Record Views

87 Times Cited - Web of Science

See more details